Fig. 7: Incorporation of growth factors into HβCD hydrogels increasing efficacy of cutaneous wound closure in ex vivo human skin model. | npj Regenerative Medicine

Fig. 7: Incorporation of growth factors into HβCD hydrogels increasing efficacy of cutaneous wound closure in ex vivo human skin model.

From: Scaffolds with spatiotemporally controlled growth factor delivery and cyclodextrin-enabled antagonism of growth factor receptor sequestration promote cutaneous wound healing

Fig. 7

a Encapsulating EGF into HβCD promotes wound re-epithelialization based on quantification of migrating epithelial tongues from H&E images [n = 4 with each point in the bar represents an independent skin donor, with bar graphs presented as mean ± SD, One-way ANOVA: **p < 0.01, ***p < 0.001, and ****p < 0.0001]. (scale bar = 500 µm) b Immunoblot analysis confirming increased bioactivity of released EGF from human ex vivo wounds treated with HβCD hydrogels. c Quantification of western blots normalized to total EGFR and total Erk1/2 for phospho-EGFR and phospho-Erk1/2 levels, respectively. d RT-qPCR validating increased expression of angiogenesis-related genes when EGF is encapsulated in HβCD hydrogels [n = 3, with each point in the bar represents an independent skin donor, bar graphs presented as mean ± SD, One-way ANOVA: **p < 0.01, ***p < 0.001, and ****p < 0.0001]. e Immunostaining of human ex vivo skin confirming increased number of blood vessel cells as quantified by CD31+ staining [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t-test, **p < 0.01]. (scale bar = 50 µm).

Back to article page